Interleukin
receptors are a group of cytokine receptors that are expressed by
leukocytes. Interleukin receptors play an important role in the functioning of
the immune system. However, with complete knowledge of their role in
pathogenesis of different diseases from allergic reactions to autoimmune
disorders and even cancer makes these interleukin receptors an attractive
target among different available treatment modalities.
Immune-modulatory role of interleukins as well as their
direct and indirect contact with apoptosis and other cancer developments,
angiogenesis and progression pathways makes them attractive targets for cancer
treatment. GlaxoSmithKline plc is in the process of developing GSK2618960 as an
interleukin 7 modulator for the treatment of Sjogren's syndrome. Some of the
other companies having pipeline of interleukin receptor modulators include
Can-Fite BioPharma Ltd., and Pfizer Inc.
The report provides a comprehensive understanding of the
pipeline activities covering all drug candidates under various stages of
development, with detailed analysis of pipeline and clinical trials. Pipeline
analysis of drugs by phases includes product description and development activities
including information about clinical results, designations, collaborations,
licencing, grants, technology and others.
